<DOC>
	<DOCNO>NCT01148615</DOCNO>
	<brief_summary>Primary Objective : - To confirm dose aflibercept western study assess dose-limiting toxicity ( DLT ) intravenous ( IV ) aflibercept administer combination docetaxel give intravenously every 3 week Chinese patient solid tumor . Secondary Objectives : - To assess safety profile intravenous ( IV ) aflibercept administer combination docetaxel - To determine pharmacokinetics IV aflibercept docetaxel administer combination - To make preliminary assessment antitumor effect combination docetaxel plus aflibercept patient evaluable disease - To evaluate immunogenicity IV aflibercept - To measure endogenous free Vascular Endothelial Growth Factor ( VEGF )</brief_summary>
	<brief_title>A Study Intravenous Aflibercept With Docetaxel Chinese Patients With Solid Tumors</brief_title>
	<detailed_description>The duration screening , treatment , follow-up within 21 day , 3 weeks/cycle , 90 day last aflibercept administration . Patients administer aflibercept combination docetaxel when/if definitive treatment discontinuation criterion meet progressive disease , unacceptable toxicity patient refusal continue .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm solid malignancy metastatic unresectable standard curative measure exist , docetaxel treatment appropriate . Exclusion criterion : Squamous histology/cytology lung cancer Need major surgical procedure radiation therapy study Treatment chemotherapy , hormonal therapy , radiotherapy , surgery , investigational agent within 28 day Cumulative radiation therapy &gt; 25 % total bone marrow History brain metastasis Eastern Cooperative Oncology Group ( ECOG ) &gt; 1 Prior docetaxel treatment appropriate safety reason Inadequate organ bone marrow function Uncontrolled hypertension Evidence clinically significant bleed diathesis underlie coagulopathy The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>